News Column

Research Conducted at Institute of Hematology and Blood Transfusion Has Provided New Information about Cancer Gene Therapy

June 16, 2014

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating in Prague, Czech Republic, by NewsRx journalists, research stated, "We constructed recombinant vaccinia viruses (VACVs) coexpressing the insulin-like growth factor-binding protein-3 (IGFBP-3) gene and the fusion gene encoding the SigE7Lamp antigen. The expression of the IGFBP-3 transgene was regulated either by the early H5 promoter or by the synthetic early/late (E/L) promoter."

The news reporters obtained a quote from the research from the Institute of Hematology and Blood Transfusion, "We have shown that IGFBP-3 expression regulated by the H5 promoter yielded higher amount of IGFBP-3 protein when compared with the E/L promoter. The immunization with P13-SigE7Lamp-H5-IGFBP-3 virus was more effective in inhibiting the growth of TC-1 tumors in mice and elicited higher T-cell response against VACV-encoded antigen than the P13-SigE7Lamp-TK(-) control virus. We found that high-level production of IGFBP-3 enhanced virus replication both in vitro and in vivo, resulting in more profound antigen stimulation. Production of IGFBP-3 was associated with a higher adsorption rate of P13-SigE7Lamp-H5-IGFBP-3 to CV-1 cells when compared with P13-SigE7Lamp-TK(-). Intracellular mature virions (IMVs) of the IGFBP-3-expressing virus P13-SigE7Lamp-H5-IGFBP-3 have two structural differences: they incorporate the IGFBP-3 protein and they have elevated phosphatidylserine (PS) exposure on outer membrane that could result in increased uptake of IMVs by macropinocytosis."

According to the news reporters, the research concluded: "The IMV PS content was measured by flow cytometry using microbeads covered with immobilized purified VACV virions."

For more information on this research see: Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3. Cancer Gene Therapy, 2014;21(3):115-25. (Nature Publishing Group -; Cancer Gene Therapy -

Our news correspondents report that additional information may be obtained by contacting J. Musil, Dept. of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Additional authors for this research include L. Kutinova, K. Zurkova, P. Hainz, K. Babiarova, J. Krystofova and S. Nemeckova (see also Biotechnology).

Keywords for this news article include: Biotechnology, Prague, Europe, Viruses, Virology, Czech Republic.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cancer Gene Therapy Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters